These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 16203650)

  • 1. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New progestagens for contraceptive use.
    Sitruk-Ware R
    Hum Reprod Update; 2006; 12(2):169-78. PubMed ID: 16291771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
    Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
    Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New progestogens: a review of their effects in perimenopausal and postmenopausal women.
    Sitruk-Ware R
    Drugs Aging; 2004; 21(13):865-83. PubMed ID: 15493951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.
    Rübig A
    Climacteric; 2003 Oct; 6 Suppl 3():49-54. PubMed ID: 15018248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
    Foidart JM
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of progestins.
    Sitruk-Ware R
    Maturitas; 2004 Apr; 47(4):277-83. PubMed ID: 15063480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
    Simoncini T; Genazzani AR
    Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
    Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
    Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drospirenone and its antialdosterone properties.
    Genazzani AR; Mannella P; Simoncini T
    Climacteric; 2007 Feb; 10 Suppl 1():11-8. PubMed ID: 17364593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of progestins. Focus on the novel progestin drospirenone.
    Thorneycroft IH
    J Reprod Med; 2002 Nov; 47(11 Suppl):975-80. PubMed ID: 12497671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
    Palacios S; Foidart JM; Genazzani AR
    Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
    Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E
    Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of newer progestins for contraception.
    Sitruk-Ware R; Nath A
    Contraception; 2010 Nov; 82(5):410-7. PubMed ID: 20933114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
    Foidart JM; Faustmann T
    Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.